Follow
Shun Lu
Shun Lu
Shanghai Chest Hospital
Verified email at csco.org.cn
Title
Cited by
Cited by
Year
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, opená…
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ...
The lancet oncology 12 (8), 735-742, 2011
49192011
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-labelá…
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
29832019
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an opená…
YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ...
The lancet oncology 15 (2), 213-222, 2014
23372014
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomisedá…
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
17722015
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
14162020
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ...
New England Journal of Medicine 386 (21), 1973-1985, 2022
13432022
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlledá…
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ...
The Lancet Oncology 17 (5), 577-589, 2016
12692016
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, opená…
L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ...
The Lancet Oncology 22 (2), 198-211, 2021
10302021
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, opená…
YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu, Y Cheng, B Han, ...
Annals of oncology 26 (9), 1883-1889, 2015
7852015
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O’Byrne, L Zhang, V Hirsh, M Boyer, JCH Yang, ...
Annals of Oncology 28 (2), 270-277, 2017
5682017
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E G÷ker, ...
The lancet oncology 16 (8), 897-907, 2015
5072015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cellá…
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ...
Annals of Oncology 26 (9), 1877-1883, 2015
4772015
BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients withá…
C Zhou, YL Wu, G Chen, X Liu, Y Zhu, S Lu, J Feng, J He, B Han, J Wang, ...
Journal of clinical oncology 33 (19), 2197-2204, 2015
4382015
The diversity of gut microbiome is associated with favorable responses to anti–programmed death 1 immunotherapy in Chinese patients with NSCLC
Y Jin, H Dong, L Xia, Y Yang, Y Zhu, Y Shen, H Zheng, C Yao, Y Wang, ...
Journal of Thoracic Oncology 14 (8), 1378-1389, 2019
4002019
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial
YL Wu, S Lu, Y Cheng, C Zhou, J Wang, T Mok, L Zhang, HY Tu, L Wu, ...
Journal of Thoracic Oncology 14 (5), 867-875, 2019
3392019
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blindá…
L Zhang, S Ma, X Song, B Han, Y Cheng, C Huang, S Yang, X Liu, Y Liu, ...
The lancet oncology 13 (5), 466-475, 2012
3212012
Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer
YL Wu, JCH Yang, DW Kim, S Lu, J Zhou, T Seto, JJ Yang, N Yamamoto, ...
Journal of clinical oncology 36 (14), 1405-1411, 2018
2992018
IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy
WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ...
Journal of Thoracic Oncology 15 (5), 709-740, 2020
2852020
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOSá…
YL Wu, D Planchard, S Lu, H Sun, N Yamamoto, DW Kim, DSW Tan, ...
Annals of Oncology 30 (2), 171-210, 2019
2792019
Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a phase 3 randomized clinical trial
J Wang, S Lu, X Yu, Y Hu, Y Sun, Z Wang, J Zhao, Y Yu, C Hu, K Yang, ...
JAMA oncology 7 (5), 709-717, 2021
2742021
The system can't perform the operation now. Try again later.
Articles 1–20